Indicators of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin-III administration for acquired antithrombin III deficiency

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 6, 1997, Pages 760-763

  Van Norman, Gail A ^a   Gernsheimer, Terry ^a   Chandler, Wayne L ^a   Cochran, R P ^a   Spiess, Bruce D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTITHROMBIN III; FENTANYL; GLYCERYL TRINITRATE; HEPARIN; ISOFLURANE; MIDAZOLAM; PANCURONIUM; PROTAMINE SULFATE;

ADULT; ANTITHROMBIN III DEFICIENCY; ARTICLE; CARDIOPULMONARY BYPASS; CASE REPORT; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; FIBRINOLYSIS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030930446     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-0770(97)90172-5     Document Type: Article

References (25)

1. Menache D, Grossman BJ, Jackson CM: Antithrombin III: Physiology, deficiency, and replacement therapy. Transfusion 32:581-588,1992
2. Marciniak E, Gockerman JP: Heparin-induced decrease in circulating antithrombin III. Lancet 2:581-584,1977
3. Hashimoto K, Yamagishi M, Sasaki T, et al: Heparin and antithrombin III levels during cardiopulmonary bypass: Correlation with subclinical plasma coagulation. Ann Thorac Surg 58:799-804, 1994
4. Tait RC, Walker ID, Davidson JF, et al: Antithrombin III activity in healthy blood donors: Age- and sex-related changes and the prevalence of asymptomatic deficiency. Br J Haematol 75:141-142, 1990 (letter)
5. Fourrier F, Chopin C, Huart JJ, et al: Double-blind, placebocontrolled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104:882-888, 1993
6. Pogliani EM, Parma M, Baragetti I, et al: L-asparaginase in acute lymphoblastic leukemia treatment: The role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy. Acta Haematol 93:5-8,1995
7. Boisclair MD, Lane DA, Philippou H, et al: Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 82:3350-3357, 1993
8. Rosenberg RD: Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 87:2S-9S, 1989
9. Kucuk O, Kwaan HC, Frederickson J, et al: Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operations. Am J Hematol 23:223-229, 1986
10. Murphy WG, Davies MJ, Eduardo A: The haemostatic response to surgery and trauma: Review article. Br J Anaesth 70:205-213, 1993
11. Khuri SF, Wolfe JA, Josa M, et al: Hematologic changes during and after cardiopulmpnary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 104:94-107, 1992
12. Kowalski E, Kopec M, Wegrzynoxicz Z: Influence of fibrinogen degradation products (FDP) on platelet aggregation, adhesiveness, and viscous metamorphosis. Thromb Diatr Haemorr 10:406-423, 1963
13. Tanaka K, Takao M, Yada I, et al: Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 3:181-188, 1989
14. Chandler WL, Fitch JC, Wall MH, et al: Individual variations in the fibrinolytic reponse during and after cardiopulmonary bypass. Thromb Haemost 74:1293-1297,1995
15. Valen G, Eriksson E, Risberg B, et al: Fibrinolysis during cardiac surgery: Release of tissue plasminogen activator in arterial and coronary sinus blood. Eur J Cardiothorac Surg 8:324-330, 1994
16. Hamsten A, de-Faire U, Walldius G, et al: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3-9, 1987
17. Sautter RD, Myers WO, Ray JF, et al: Relationship of the fibrinolytic system to postoperative thrombotic phenomena. Arch Surg 107:292-296,1983
18. Tinker JH, Roberts SL: Management of cardiopulmonary bypass, in Kaplan JA (ed): Cardiac Anesthesia (ed 2). London, UK, Grune & Stratton, 1987, pp 895-926
19. Grodman-Gross CA, Sastri SV: Heparin associated hematomas: Possible allergic reaction. Drug Intell Clin Pharm 21:180-183, 1987
20. Young JA, Kisker CT, Doty DB: Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 26:231-240, 1978
21. Uppington J: Anesthetic management of patients with coagulation disorders. Int Anesthesiol Clin 23:125-140, 1985
22. Piszkiewicz D, Apfelzweig R, Bourret L, et al: Inactivation of HIV in antithrombin III concentrate by pasteurization. Transfusion 28:198-199, 1988 (letter)
23. Menache D, O'Malley JP, Schorr JB, et al: Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 75:33-39, 1990
24. Tabor E, Murano G, Snoy P, et al: Inactivation of hepatitis B virus by heat in antithrombin III stabilized with citrate. Thromb Res 22:233-238, 1981
25. Forbes JM, Anderson MD, Anderson GF, et al: Blood transfusion costs: A multicenter study. Transfusion 31:318-323, 1991